Mozobil in combination with G-CSF can be used to mobilize blood stem cells for transplantation in NHL and MM patients.
Genzyme won approval for Mozobil™ to be used in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the bloodstream for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM). The company expects peak sales in the transplant setting to reach $400 million annually.
In addition to its expected benefits for patients with NHL and MM, Mozobil may offer economic benefits for transplant centers, Genzyme reports. The product has the potential to decrease the number of apheresis days and provide transplant centers with predictable and efficient use of the apheresis center. Mozobil may also reduce the number of patients who require a second mobilization procedure due to a failure to mobilize sufficient numbers of cells with current therapy.
Genzyme submitted an MAA in Europe for Mozobil and expects a sanction in the second half of 2009. It also recently filed applications in Australia and Brazil and more applications in up to 60 countries are planned. With orphan drug designation in Mexico and with U.S. approval, Mozobil can now be commercialized in that country.
Mozobil is a small molecule CXCR4 chemokine receptor antagonist. Genzyme has been developing Mozobil since its acquisition of AnorMED in 2006.